-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
-
Summary
-
Nurix Therapeutics, Inc. quarterly Deferred Tax Assets, Gross history and growth rate from Q4 2019 to Q4 2023.
- Nurix Therapeutics, Inc. Deferred Tax Assets, Gross for the quarter ending November 30, 2023 was $203M, a 43.1% increase year-over-year.
Deferred Tax Assets, Gross, Quarterly (USD)
Deferred Tax Assets, Gross, YoY Quarterly Growth (%)